CN1751064A - 节杆菌来源的hsp60 - Google Patents
节杆菌来源的hsp60 Download PDFInfo
- Publication number
- CN1751064A CN1751064A CNA2004800041383A CN200480004138A CN1751064A CN 1751064 A CN1751064 A CN 1751064A CN A2004800041383 A CNA2004800041383 A CN A2004800041383A CN 200480004138 A CN200480004138 A CN 200480004138A CN 1751064 A CN1751064 A CN 1751064A
- Authority
- CN
- China
- Prior art keywords
- sequence
- hsp60
- arthrobacter
- nucleotide sequence
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000186063 Arthrobacter Species 0.000 title claims abstract description 74
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 title description 10
- 101710154868 60 kDa heat shock protein, mitochondrial Proteins 0.000 title description 10
- 108091007433 antigens Proteins 0.000 claims abstract description 56
- 102000036639 antigens Human genes 0.000 claims abstract description 56
- 239000000427 antigen Substances 0.000 claims abstract description 55
- 241000251468 Actinopterygii Species 0.000 claims abstract description 40
- 101150023414 HSP60 gene Proteins 0.000 claims abstract description 25
- 230000002163 immunogen Effects 0.000 claims abstract description 14
- 108010058432 Chaperonin 60 Proteins 0.000 claims description 118
- 102000006303 Chaperonin 60 Human genes 0.000 claims description 116
- 229960005486 vaccine Drugs 0.000 claims description 62
- 239000002773 nucleotide Substances 0.000 claims description 53
- 125000003729 nucleotide group Chemical group 0.000 claims description 53
- 150000001413 amino acids Chemical class 0.000 claims description 43
- 235000019688 fish Nutrition 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 37
- 239000013604 expression vector Substances 0.000 claims description 29
- 108020004414 DNA Proteins 0.000 claims description 28
- 235000001014 amino acid Nutrition 0.000 claims description 24
- 230000004927 fusion Effects 0.000 claims description 24
- 239000012634 fragment Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 23
- 150000007523 nucleic acids Chemical group 0.000 claims description 23
- 241001465754 Metazoa Species 0.000 claims description 21
- 241000700605 Viruses Species 0.000 claims description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
- 230000001580 bacterial effect Effects 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 14
- 238000000926 separation method Methods 0.000 claims description 14
- 241000972773 Aulopiformes Species 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 12
- 235000019515 salmon Nutrition 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 108091026890 Coding region Proteins 0.000 claims description 7
- 230000004044 response Effects 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 241000606701 Rickettsia Species 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000000735 allogeneic effect Effects 0.000 claims description 5
- 230000002103 transcriptional effect Effects 0.000 claims description 5
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 208000013223 septicemia Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000006353 environmental stress Effects 0.000 claims description 3
- 230000036039 immunity Effects 0.000 claims description 3
- 230000002458 infectious effect Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 208000009663 Acute Necrotizing Pancreatitis Diseases 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 241000244206 Nematoda Species 0.000 claims description 2
- 206010058096 Pancreatic necrosis Diseases 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 244000037640 animal pathogen Species 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000012646 vaccine adjuvant Substances 0.000 claims 1
- 229940124931 vaccine adjuvant Drugs 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 65
- 102000004169 proteins and genes Human genes 0.000 abstract description 34
- 239000002671 adjuvant Substances 0.000 abstract description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 55
- 210000004027 cell Anatomy 0.000 description 45
- 108090000765 processed proteins & peptides Proteins 0.000 description 36
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 33
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 31
- 235000018102 proteins Nutrition 0.000 description 30
- 102000004196 processed proteins & peptides Human genes 0.000 description 25
- 229920001184 polypeptide Polymers 0.000 description 24
- 229940024606 amino acid Drugs 0.000 description 19
- 239000013612 plasmid Substances 0.000 description 14
- 238000011081 inoculation Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 10
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 10
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 229940023146 nucleic acid vaccine Drugs 0.000 description 10
- 230000000890 antigenic effect Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 230000001717 pathogenic effect Effects 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 230000008521 reorganization Effects 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 244000052769 pathogen Species 0.000 description 6
- 238000011238 DNA vaccination Methods 0.000 description 5
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 5
- 101710081079 Minor spike protein H Proteins 0.000 description 5
- 241000186359 Mycobacterium Species 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 238000013459 approach Methods 0.000 description 4
- -1 fraction Substances 0.000 description 4
- 238000013467 fragmentation Methods 0.000 description 4
- 238000006062 fragmentation reaction Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 102220023257 rs387907546 Human genes 0.000 description 4
- 102220023258 rs387907548 Human genes 0.000 description 4
- 239000012266 salt solution Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000009184 walking Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 3
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 3
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 3
- 241000277263 Salmo Species 0.000 description 3
- 241000607598 Vibrio Species 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- ABQGFYSYSCHJNB-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 5-(pyridin-2-yldisulfanyl)pentanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCSSC1=CC=CC=N1 ABQGFYSYSCHJNB-UHFFFAOYSA-N 0.000 description 2
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 description 2
- 241000607534 Aeromonas Species 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 101000805768 Banna virus (strain Indonesia/JKT-6423/1980) mRNA (guanine-N(7))-methyltransferase Proteins 0.000 description 2
- 241000711895 Bovine orthopneumovirus Species 0.000 description 2
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 2
- 241000589562 Brucella Species 0.000 description 2
- 101000686790 Chaetoceros protobacilladnavirus 2 Replication-associated protein Proteins 0.000 description 2
- 101000864475 Chlamydia phage 1 Internal scaffolding protein VP3 Proteins 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- 241000223935 Cryptosporidium Species 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 2
- 241000223924 Eimeria Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101000803553 Eumenes pomiformis Venom peptide 3 Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000605909 Fusobacterium Species 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101150031823 HSP70 gene Proteins 0.000 description 2
- 101000583961 Halorubrum pleomorphic virus 1 Matrix protein Proteins 0.000 description 2
- 241000606831 Histophilus somni Species 0.000 description 2
- 241000711804 Infectious hematopoietic necrosis virus Species 0.000 description 2
- 101900217743 Infectious pancreatic necrosis virus Capsid protein VP2 Proteins 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 241000222722 Leishmania <genus> Species 0.000 description 2
- 241000589902 Leptospira Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001293418 Mannheimia haemolytica Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 241001138504 Mycoplasma bovis Species 0.000 description 2
- 241000204045 Mycoplasma hyopneumoniae Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 241000606860 Pasteurella Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000186812 Renibacterium salmoninarum Species 0.000 description 2
- 241001660014 Salmon pancreas disease virus Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000277331 Salmonidae Species 0.000 description 2
- 241001492212 Striped Jack nervous necrosis virus Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 241001265687 Taura syndrome virus Species 0.000 description 2
- 241000696962 White spot syndrome virus Species 0.000 description 2
- 241000380111 Yellow head virus Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000001364 causal effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000013368 commensalism Effects 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 101150052825 dnaK gene Proteins 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000013505 freshwater Substances 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 101150077981 groEL gene Proteins 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000005562 infectious bovine rhinotracheitis Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 102220023256 rs387907547 Human genes 0.000 description 2
- 239000013535 sea water Substances 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NQTSTBMCCAVWOS-UHFFFAOYSA-N 1-dimethoxyphosphoryl-3-phenoxypropan-2-one Chemical compound COP(=O)(OC)CC(=O)COC1=CC=CC=C1 NQTSTBMCCAVWOS-UHFFFAOYSA-N 0.000 description 1
- CVOFKRWYWCSDMA-UHFFFAOYSA-N 2-chloro-n-(2,6-diethylphenyl)-n-(methoxymethyl)acetamide;2,6-dinitro-n,n-dipropyl-4-(trifluoromethyl)aniline Chemical compound CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl.CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O CVOFKRWYWCSDMA-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000606646 Anaplasma Species 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 241000473391 Archosargus rhomboidalis Species 0.000 description 1
- 241000186073 Arthrobacter sp. Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001148534 Brachyspira Species 0.000 description 1
- 101100439426 Bradyrhizobium diazoefficiens (strain JCM 10833 / BCRC 13528 / IAM 13628 / NBRC 14792 / USDA 110) groEL4 gene Proteins 0.000 description 1
- 241000036569 Carp sprivivirus Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000605314 Ehrlichia Species 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 241000321429 Epinephelus itajara Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 241000276438 Gadus morhua Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 241000701372 Iridovirus Species 0.000 description 1
- 125000000010 L-asparaginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- FMIIKPHLJKUXGE-GUBZILKMSA-N Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN FMIIKPHLJKUXGE-GUBZILKMSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 241001147660 Neospora Species 0.000 description 1
- 108700006640 OspA Proteins 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241001517016 Photobacterium damselae Species 0.000 description 1
- 241000192126 Piscirickettsia salmonis Species 0.000 description 1
- 241001600434 Plectroglyphidodon lacrymatus Species 0.000 description 1
- 241000269980 Pleuronectidae Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 1
- 241000186813 Renibacterium Species 0.000 description 1
- 241000190932 Rhodopseudomonas Species 0.000 description 1
- 241000606651 Rickettsiales Species 0.000 description 1
- 241000277289 Salmo salar Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000605008 Spirillum Species 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- 241001454698 Teleostei Species 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 206010047400 Vibrio infections Diseases 0.000 description 1
- 208000001449 Viral Hemorrhagic Septicemia Diseases 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241001148129 Yersinia ruckeri Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 101150099105 alien gene Proteins 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- WXNRAKRZUCLRBP-UHFFFAOYSA-N avridine Chemical compound CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC WXNRAKRZUCLRBP-UHFFFAOYSA-N 0.000 description 1
- 229950010555 avridine Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 102220369445 c.668T>C Human genes 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 208000000292 ehrlichiosis Diseases 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 108091008915 immune receptors Proteins 0.000 description 1
- 102000027596 immune receptors Human genes 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 241000238565 lobster Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000000101 transmission high energy electron diffraction Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6043—Heat shock proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (35)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0303507.8 | 2003-02-14 | ||
GBGB0303507.8A GB0303507D0 (en) | 2003-02-14 | 2003-02-14 | Organic compounds |
PCT/EP2004/001368 WO2004071387A2 (en) | 2003-02-14 | 2004-02-13 | Hsp60 from arthrobacter |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1751064A true CN1751064A (zh) | 2006-03-22 |
CN1751064B CN1751064B (zh) | 2010-05-26 |
Family
ID=9953082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2004800041383A Expired - Fee Related CN1751064B (zh) | 2003-02-14 | 2004-02-13 | 节杆菌来源的hsp60 |
Country Status (20)
Country | Link |
---|---|
US (2) | US7297783B2 (zh) |
EP (1) | EP1597274B1 (zh) |
JP (1) | JP5561892B2 (zh) |
CN (1) | CN1751064B (zh) |
AT (1) | ATE437177T1 (zh) |
AU (1) | AU2004212322B2 (zh) |
CA (1) | CA2513061C (zh) |
CL (1) | CL2004000262A1 (zh) |
CY (1) | CY1109349T1 (zh) |
DE (1) | DE602004022138D1 (zh) |
DK (1) | DK1597274T3 (zh) |
ES (1) | ES2328140T3 (zh) |
GB (1) | GB0303507D0 (zh) |
HK (1) | HK1085487A1 (zh) |
IS (1) | IS8018A (zh) |
NO (1) | NO20054239L (zh) |
NZ (1) | NZ541507A (zh) |
PT (1) | PT1597274E (zh) |
SI (1) | SI1597274T1 (zh) |
WO (1) | WO2004071387A2 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105039221A (zh) * | 2015-08-07 | 2015-11-11 | 中国农业科学院哈尔滨兽医研究所 | 一株冷水鱼益生菌节杆菌菌株及其用途 |
WO2023078279A1 (zh) * | 2021-11-04 | 2023-05-11 | 澄交生物科技股份有限公司 | 免疫原性组合物及其用途 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1523330E (pt) * | 2002-07-15 | 2009-09-29 | Novartis Ag | Vacina contra a septicémia rickettsial dos salmonídeos |
CN113493788B (zh) * | 2021-05-24 | 2023-06-23 | 上海晶诺生物科技有限公司 | 一种分枝杆菌启动子库及其应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1548388A (en) * | 1987-02-02 | 1988-08-24 | Whitehead Institute For Biomedical Research | Mycobacterium tuberculosis genes and encoding protein antigens |
US5165925A (en) * | 1989-05-02 | 1992-11-24 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Vaccine for immunizing fish against infectious pancreatic necrosis virus |
FR2666588B1 (fr) * | 1990-09-10 | 1994-02-11 | Pasteur Institut | Sequence nucleotidique regulatrice de l'initiation de transcription. |
JPH08510756A (ja) * | 1993-06-04 | 1996-11-12 | ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ | ストレス蛋白質とその使用 |
WO1997006828A1 (en) * | 1995-08-18 | 1997-02-27 | Sloan-Kettering Institute For Cancer Research | Method for treatment of cancer and infectious diseases and compositions useful in same |
IL136821A0 (en) | 1997-12-23 | 2001-06-14 | Genesis Res & Dev Corp Ltd | Compositions derived from mycobacterium vaccae and methods for their use |
CN1367875A (zh) | 1999-07-08 | 2002-09-04 | 斯特思吉生物技术公司 | 活体外th1一样反应的诱导方法 |
EP1206560B1 (de) * | 1999-08-26 | 2005-11-09 | BASF Plant Science GmbH | Pflanzliche genexpression unter der kontrolle von konstitutiven pflanzlichen v-atpase promotoren |
AU7033400A (en) | 1999-08-30 | 2001-03-26 | Jehad Mikhaiel Charo | Induction of cytotoxic t lymphocyte response by hla class ia restricted epitopesof mycobacterial heat shock protein 65 |
WO2002062959A2 (en) * | 2001-02-05 | 2002-08-15 | Stressgen Biotechnologies Corp. | Hepatitis b virus treatment |
GB0216414D0 (en) * | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
-
2003
- 2003-02-14 GB GBGB0303507.8A patent/GB0303507D0/en not_active Ceased
-
2004
- 2004-02-13 AU AU2004212322A patent/AU2004212322B2/en not_active Ceased
- 2004-02-13 CA CA2513061A patent/CA2513061C/en not_active Expired - Fee Related
- 2004-02-13 ES ES04710796T patent/ES2328140T3/es not_active Expired - Lifetime
- 2004-02-13 JP JP2006501838A patent/JP5561892B2/ja not_active Expired - Fee Related
- 2004-02-13 PT PT04710796T patent/PT1597274E/pt unknown
- 2004-02-13 AT AT04710796T patent/ATE437177T1/de not_active IP Right Cessation
- 2004-02-13 DK DK04710796T patent/DK1597274T3/da active
- 2004-02-13 EP EP04710796A patent/EP1597274B1/en not_active Expired - Lifetime
- 2004-02-13 CL CL200400262A patent/CL2004000262A1/es unknown
- 2004-02-13 NZ NZ541507A patent/NZ541507A/en not_active IP Right Cessation
- 2004-02-13 CN CN2004800041383A patent/CN1751064B/zh not_active Expired - Fee Related
- 2004-02-13 SI SI200431244T patent/SI1597274T1/sl unknown
- 2004-02-13 DE DE602004022138T patent/DE602004022138D1/de not_active Expired - Lifetime
- 2004-02-13 WO PCT/EP2004/001368 patent/WO2004071387A2/en active Application Filing
- 2004-02-13 US US10/543,366 patent/US7297783B2/en not_active Expired - Fee Related
-
2005
- 2005-09-12 IS IS8018A patent/IS8018A/is unknown
- 2005-09-13 NO NO20054239A patent/NO20054239L/no not_active Application Discontinuation
-
2006
- 2006-05-15 HK HK06105601.4A patent/HK1085487A1/xx not_active IP Right Cessation
-
2007
- 2007-10-26 US US11/924,986 patent/US7803924B2/en not_active Expired - Fee Related
-
2009
- 2009-08-28 CY CY20091100901T patent/CY1109349T1/el unknown
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105039221A (zh) * | 2015-08-07 | 2015-11-11 | 中国农业科学院哈尔滨兽医研究所 | 一株冷水鱼益生菌节杆菌菌株及其用途 |
CN105039221B (zh) * | 2015-08-07 | 2019-04-16 | 中国农业科学院哈尔滨兽医研究所 | 一株冷水鱼益生菌节杆菌菌株及其用途 |
WO2023078279A1 (zh) * | 2021-11-04 | 2023-05-11 | 澄交生物科技股份有限公司 | 免疫原性组合物及其用途 |
Also Published As
Publication number | Publication date |
---|---|
CY1109349T1 (el) | 2014-07-02 |
ATE437177T1 (de) | 2009-08-15 |
DE602004022138D1 (de) | 2009-09-03 |
ES2328140T3 (es) | 2009-11-10 |
WO2004071387A2 (en) | 2004-08-26 |
US7803924B2 (en) | 2010-09-28 |
CA2513061C (en) | 2015-12-22 |
JP2006517406A (ja) | 2006-07-27 |
WO2004071387A3 (en) | 2005-03-24 |
EP1597274A2 (en) | 2005-11-23 |
SI1597274T1 (sl) | 2009-12-31 |
IS8018A (is) | 2005-09-12 |
NO20054239L (no) | 2005-11-03 |
AU2004212322A1 (en) | 2004-08-26 |
US20080287664A1 (en) | 2008-11-20 |
PT1597274E (pt) | 2009-08-24 |
NZ541507A (en) | 2008-03-28 |
CL2004000262A1 (es) | 2005-03-28 |
EP1597274B1 (en) | 2009-07-22 |
US20060127416A1 (en) | 2006-06-15 |
CA2513061A1 (en) | 2004-08-26 |
DK1597274T3 (da) | 2009-11-23 |
NO20054239D0 (no) | 2005-09-13 |
GB0303507D0 (en) | 2003-03-19 |
US7297783B2 (en) | 2007-11-20 |
JP5561892B2 (ja) | 2014-07-30 |
CN1751064B (zh) | 2010-05-26 |
AU2004212322B2 (en) | 2008-01-17 |
HK1085487A1 (en) | 2006-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1055024C (zh) | 胸膜肺炎放线杆菌亚单元疫苗 | |
CN1193094C (zh) | 虾白斑综合征病毒抗原蛋白及其用途 | |
NO337573B1 (no) | Kimær nukleinsyresekvens omfattende Hsp70-sekvensen fra Arthrobacter og nukleinsyre-ekspresjonsvektor omfattende denne, vertcelle og fusjonsprotein, samt vaksinepreparet og anvendelser for fremstilling av et vaksinepreparat for vaksinering av fisk eller et medikament for forebyggelse eller behandling av infeksiøs sykdom hos fisk. | |
CN1484532A (zh) | 增强低免疫原性抗原的免疫原性的药物组合物 | |
CN1046463A (zh) | 无毒微生物及其应用 | |
CA2407301C (en) | Hsp60 sequence from piscirickettsia salmonis | |
US7803924B2 (en) | HSP60 from arthrobacter | |
WO2014118385A1 (en) | The use of dna sequences encoding an interferon as vaccine adjuvants | |
EP1523330A2 (en) | Vaccine against salmonid rickettsial septicaemia based on arthrobacter cells | |
Kamalii et al. | Advanced developments in fish vaccination | |
CN1089607C (zh) | 抗卷旋杆菌的菌苗复合物 | |
US7842296B2 (en) | Sequences from Piscirickettsia salmonis | |
CN111420041A (zh) | 水产病原菌糖酵解途径中持家酶的广谱组合型疫苗及其应用 | |
CN1763105A (zh) | 激发机体产生fmdv抗体的融合蛋白及其编码基因与应用 | |
Nagabhushanam | Subunit Vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: NOVARTIS CO., LTD. Free format text: FORMER NAME: NOVARTIS AG |
|
CP01 | Change in the name or title of a patent holder |
Address after: Basel Patentee after: Novartis Ag Address before: Basel Patentee before: Novartis AG |
|
ASS | Succession or assignment of patent right |
Owner name: SWISS NOVARTIS ANIMAL HEALTH CO., LTD. Free format text: FORMER OWNER: NOVARTIS CO., LTD. Effective date: 20150424 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150424 Address after: Basel Patentee after: Animal health company limited of Novartis of Switzerland Address before: Basel Patentee before: Novartis Ag |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100526 Termination date: 20170213 |
|
CF01 | Termination of patent right due to non-payment of annual fee |